secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001104659-26-031715
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata delays Q4/FY2025 earnings; FDA grants QIDP for phage candidate AP-SA02
-----------------------------------------------------------------------------

- Will delay Q4/FY2025 financial results announcement; expects to file 10-K by March 31, 2026 due date.
- FDA granted QIDP for AP-SA02 (S. aureus phage) as adjunct treatment for complicated bacteremia, adding Hatch-Waxman exclusivity.
- FDA alignment reached on Phase 3 superiority study design; Armata plans to initiate study in H2 2026.
- cGMP manufacturing facility in Los Angeles (~56,000 sq ft) formally commissioned; full production runs completed.
- Phase 2a diSArm study showed higher cure rates with AP-SA02 plus antibiotics vs antibiotics alone; results presented at IDWeek 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465926031715/0001104659-26-031715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465926031715/tm269341d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-031715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer